Publications by authors named "MA Tomai"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

7,227

Total Likes

216

Extended Reach

303,098

Social Features

61
C
Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine.
William R Lykins, Jeroen Pollet, Jessica A White, Brian Keegan, Leroy Versteeg, Mark A Tomai

Front Drug Deliv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of an adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques.
Mayuresh M Abhyankar, Feifan Xu, Deborah Chavez, Anna Goodroe, Elda Mendoza, Mark A Tomai

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.
William R Lykins, Jeroen Pollet, Jessica A White, Brian Keegan, Leroy Versteeg, Mark A Tomai

Front Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.
Kevin Wiehe, Kevin O Saunders, Victoria Stalls, Derek W Cain, Sravani Venkatayogi, Mark A Tomai

Cell Host Microbe· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.
Dapeng Li, David R Martinez, Alexandra Schäfer, Haiyan Chen, Maggie Barr, Mark A Tomai

Nat Commun· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection.
Kevin O Saunders, Robert J Edwards, Kedamawit Tilahun, Kartik Manne, Xiaozhi Lu, Mark A Tomai

Sci Transl Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine.
Dapeng Li, David R Martinez, Alexandra Schäfer, Haiyan Chen, Maggie Barr, Mark A Tomai

bioRxiv· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques.
Stella J Berendam, Papa K Morgan-Asiedu, Riley J Mangan, Shuk Hang Li, Holly Heimsath, Mark A Tomai

PLoS One· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing a Multi-Component Intranasal Vaccine Formulation Using a Design of Experiments Strategy.
Mayuresh M Abhyankar, Mark T Orr, Robert Kinsey, Sandra Sivananthan, Andrew J Nafziger, Mark A Tomai

Front Immunol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.
Mayuresh M Abhyankar, Barbara J Mann, Jeffrey M Sturek, Savannah Brovero, G Brett Moreau, Mark A Tomai

NPJ Vaccines· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
Maria Pino, Talha Abid, Susan Pereira Ribeiro, Venkata Viswanadh Edara, Katharine Floyd, Mark A Tomai

Sci Immunol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys.
Kevin O Saunders, Esther Lee, Robert Parks, David R Martinez, Dapeng Li, Mark A Tomai

bioRxiv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Stefanie R Mullins, John P Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Mark A Tomai

J Immunother Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for .
Mayuresh M Abhyankar, Mark T Orr, Susan Lin, Mohammed O Suraju, Adrian Simpson, Mark A Tomai

NPJ Vaccines· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.
David J Dowling, Simon D van Haren, Annette Scheid, Ilana Bergelson, Dhohyung Kim, Mark A Tomai

JCI Insight· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
Mayuresh M Abhyankar, Zannatun Noor, Mark A Tomai, James Elvecrog, Christopher B Fox

Vaccine· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.
Christopher B Fox, Mark T Orr, Neal Van Hoeven, Sarah C Parker, Traci J T Mikasa, Mark A Tomai

J Control Release· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
Sebastian Schölch, Conrad Rauber, Alexandra Tietz, Nuh N Rahbari, Ulrich Bork, Mark A Tomai

Oncotarget· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
John P Vasilakos, Mark A Tomai

Expert Rev Vaccines· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR-7 and -8 agonists as vaccine adjuvants.
Mark A Tomai, John P Vasilakos

Expert Rev Vaccines· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.
Calin D Dumitru, Mary A Antonysamy, Mark A Tomai, Kenneth E Lipson

Cancer Biol Ther· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
Calin D Dumitru, Mary A Antonysamy, Kevin S Gorski, Dave D Johnson, Laxma G Reddy, Mark A Tomai

Cancer Immunol Immunother· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
Jon R Inglefield, Calin Dan Dumitru, Sefik S Alkan, Sheila J Gibson, Kenneth E Lipson, Mark A Tomai

J Interferon Cytokine Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antiviral activity of Toll-like receptor 7 and 7/8 agonists.
Richard L Miller, Tze-Chiang Meng, Mark A Tomai

Drug News Perspect· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis